<DOC>
	<DOCNO>NCT01691768</DOCNO>
	<brief_summary>The purpose study assess effectiveness implementation model integrate tenofovir gel provision exist family planning service .</brief_summary>
	<brief_title>Implementation Effectiveness Safety Tenofovir Gel Provision Through Family Planning Services</brief_title>
	<detailed_description>The CAPRISA 008 trial two-arm , open-label , randomize control trial conduct CAPRISA eThekwini CAPRISA Vulindlela Clinics neighbor public sector family planning service KwaZulu-Natal , South Africa . Up 700 consent sexually active , HIV-uninfected woman age 18 year old previously participate antiretroviral ( ARV ) prevention study enrol follow maximum 30 month . All woman provide 1 % tenofovir gel randomise either receive gel public sector family planning service 2-3 monthly provision ( intervention arm ) CAPRISA research clinic monthly provision ( control arm ) . All woman trial provide standard package HIV prevention reproductive health service . Participants study arm provide supply single-use , pre-filled applicator 1 % tenofovir gel . While study , participant advise support follow CAPRISA 004 pre- post-dosing strategy , namely BAT24 , first dose tenofovir gel apply within 12 hour anticipate coitus second dose soon possible within 12 hour coitus , maximum two dos gel 24-hour period . The primary objective trial ass effectiveness implementation model tenofovir gel provision family planning service .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 18 year old Women previously participate ARV prevention study Currently utilize agree attend designate public sector family planning service Able willing provide first person informed consent screen , enroll , study Able willing provide adequate locator information study retention purpose Sexually active ( least one coital act last 3 month prior screen ) HIV negative ( HIV test perform study staff within 30 day enrollment ) Negative pregnancy test perform study staff within 21 day enrollment Agree use nonbarrier form contraceptive Agree adhere study visit procedure Has creatinine clearance &lt; 50ml/min Has condition , base opinion Investigator designee , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>microbicides</keyword>
	<keyword>woman</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>PrEP</keyword>
	<keyword>Tenofovir gel</keyword>
</DOC>